


Global Day Against Pain 17th October, Alicante, Spain



Roundtable, **The Steep Path from Basic Science to Novel Pain Therapies**

Salón de Actos, Instituto de Neurociencias UMH-CSIC

11:30 Coffee

12:00-12:10 Introduction, Felix Viana, Director SP5 Research Program

12:10-12:30 Prof. Michaela Kress
Director Institute of Physiology
University of Innsbruck Medical School (Austria)

“Cytokines regulating ion channels in neuropathic pain”

12:30-12:50 Prof. Antonio Ferrer-Montiel
Director IDiBE
Universidad Miguel Hernández de Elche (Spain)

“Should all analgesics be oral drugs? Opportunities for topical formulations in pain intervention”

12:50-13:10 Dr. Edward Emery
Director Translational Science Grünenthal (United Kingdom)

“Bench to bedside and back again - challenges of analgesic translation”

13:10-14:00 Round Table

Organizing Committee

Elvira de la Peña

Jorge Fernández Trillo

Félix Viana

Instituto de Neurociencias, UMH-CSIC

Global Day Against Pain

17th October, Alicante, Spain

Purpose of the round table

Chronic pain is a major sociosanitary problem, affecting millions of patients worldwide, and novel therapies for its treatment are highly demanded in the clinic. Unfortunately, despite this urgent need, progress in the development of new pain therapies over the past three decades has been slow and disappointing. This is due to a combination of scientific, clinical, and regulatory challenges. They include: the diversity of pain mechanisms, the high variability in pain perception and response among patients that complicates clinical trial design and outcome interpretation. The poor predictive value of current preclinical models adds to the slow progress. Clinical pain trials are also complicated by the placebo effect and the interpretation of results (pain ratings are subjective). Finally, the opioid crisis has led to increased regulatory demands for safety.

The three participants in the round table have significant and complementary experience in tackling many of these challenges. They will share their experience and insight into finding ways to address this problem, offering hope for chronic pain patients and society at large.

Brief biosketch of participants

Prof. Michaela Kress, MD PhD, is Director of the Institute of Physiology at the University of Innsbruck Medical School. She is also the head of the Physiology and Pathophysiology of the Nociceptive System Group. Her laboratory has made important contributions to our understanding of the development of nociceptors neurons and their modulation by different extrinsic signals, including the immune system.

Prof. Antonio Ferrer-Montiel, PhD, is Director of IDiBE and Professor of Biochemistry at the Universidad Miguel Hernández (Elche, Spain). His main interests is the development of novel analgesic therapies targeting ion channels and neurotransmitters. He has been involved in the funding and development of several biotech companies and spin-offs in the biomedical field.

Dr. Edward Emery, PhD, is Director of Translational Science research at Grünenthal. His interests are in the development of non-opioid analgesics, specifically those targeting ion channels and neuroimmune pathways. Prior to joining Grünenthal, he held similar positions at AZ and GSK and has been involved in the progression of numerous analgesic targets into the clinic.

